Literature DB >> 12403135

Autoimmune sensorineural hearing loss improved by tumor necrosis factor-alpha blockade: a case report.

H Staecker1, P P Lefebvre.   

Abstract

Autoimmune inner ear disease is a treatable cause of sensorineural hearing loss and it is important for physicians and hearing health professionals to recognize that early diagnosis and proper management strategies may result in stabilization and improvement in hearing. The pathogenesis of autoimmune sensorineural hearing loss remains unclear but antibodies directed against the inner ear and/or cellular effectors have been proposed. Therefore, immunosuppressive drugs such as steroids and methotrexate are administered to interfere with the progression of hearing loss and in some cases have been found to improve hearing. We report herein the history of a patient who was treated by systemic administration of anti-tumor necrosis factor-alpha antibodies for Crohn's disease and who also had associated sensorineural hearing loss. Audiometric follow-up revealed not only the efficacy of tumor necrosis factor-alpha blockade in arresting the hearing loss but also an improvement in hearing of 15 dB on average across all frequencies. Hearing remained stable afterwards.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12403135     DOI: 10.1080/000164802320396402

Source DB:  PubMed          Journal:  Acta Otolaryngol        ISSN: 0001-6489            Impact factor:   1.494


  10 in total

1.  Acute sensorineural hearing loss as an early manifestation of indeterminate colitis.

Authors:  Bret J Spier; John Bryant Wyman; Mark Reichelderfer; Darren C Schwartz
Journal:  Dig Dis Sci       Date:  2004-08       Impact factor: 3.199

2.  Alternatives to systemic steroid therapy for refractory immune-mediated inner ear disease: A physiopathologic approach.

Authors:  José Ramón García-Berrocal; Andrés Ibáñez; Antonio Rodríguez; José Angel González-García; José María Verdaguer; Almudena Trinidad; Rafael Ramírez-Camacho
Journal:  Eur Arch Otorhinolaryngol       Date:  2006-06-27       Impact factor: 2.503

3.  Sensorineural hearing loss in patients with inflammatory bowel disease: a subclinical extraintestinal manifestation.

Authors:  Nihat Akbayir; Asli Batur Caliş; Canan Alkim; H Mehmet Mehmet Sökmen; Levent Erdem; Ayça Ozbal; Füsun Bölükbaş; Nihat Akbayir
Journal:  Dig Dis Sci       Date:  2005-10       Impact factor: 3.199

Review 4.  Biological therapies in otology.

Authors:  A Roemer; H Staecker; S Sasse; T Lenarz; A Warnecke
Journal:  HNO       Date:  2017-08       Impact factor: 1.284

5.  [Biological therapies in otology. German version].

Authors:  A Roemer; H Staecker; S Sasse; T Lenarz; A Warnecke
Journal:  HNO       Date:  2017-07       Impact factor: 1.284

6.  TNFalpha blockers do not improve the hearing recovery obtained with glucocorticoid therapy in an autoimmune experimental labyrinthitis.

Authors:  David Lobo; Almudena Trinidad; José Ramón García-Berrocal; Jose María Verdaguer; Rafael Ramírez-Camacho
Journal:  Eur Arch Otorhinolaryngol       Date:  2006-03-18       Impact factor: 2.503

7.  Hearing Loss in Patients with Inflammatory Bowel Disease.

Authors:  Dov Wengrower; Benjamin Koslowsky; Uri Peleg; Betty Mazuz; Leore Cohen; Allin Ben-David; Menahem Gross; Eran Goldin; Chanan Shaul
Journal:  Dig Dis Sci       Date:  2016-04-05       Impact factor: 3.199

Review 8.  Ear Involvement in Inflammatory Bowel Disease: A Review of the Literature.

Authors:  Fotios S Fousekis; Maria Saridi; Eleni Albani; Fady Daniel; Konstantinos H Katsanos; Ioannis G Kastanioudakis; Dimitrios K Christodoulou
Journal:  J Clin Med Res       Date:  2018-06-27

Review 9.  Evidence Supporting the Hypothesis That Inflammation-Induced Vasospasm Is Involved in the Pathogenesis of Acquired Sensorineural Hearing Loss.

Authors:  Michael Eisenhut
Journal:  Int J Otolaryngol       Date:  2019-11-06

Review 10.  Bilateral sudden sensorineural hearing loss as a presenting feature of systemic lupus erythematosus: Case report and brief review of other published cases.

Authors:  Sylvain Chawki; Jessie Aouizerate; Selim Trad; Jacques Prinseau; Thomas Hanslik
Journal:  Medicine (Baltimore)       Date:  2016-09       Impact factor: 1.889

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.